India's GLP-1 boom slows amid price war, weak retention

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-expected prescriptions and patient retention. Unexpected price cuts from the innovator, coupled with the high cost of generics for Indian consumers, are impacting adoption. This has led to a wait-and-watch approach for upcoming launches, with a potential revival anticipated later in the fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kmvBXf
via IFTTT